Current Opinion in Oncology最新文献_第3页

Haemophagocytic lymphohistiocytosis: a life threatening complication of lymphoma. 噬血细胞性淋巴组织细胞增多症：淋巴瘤的一种危及生命的并发症。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-09-01 Epub Date: 2026-07-21 DOI: 10.1097/CCO.0000000000001259

Pierre Antoine

{"title":"Haemophagocytic lymphohistiocytosis: a life threatening complication of lymphoma.","authors":"Pierre Antoine","doi":"10.1097/CCO.0000000000001259","DOIUrl":"10.1097/CCO.0000000000001259","url":null,"abstract":"Purpose of review: Haemophagocytic lymphohistiocytosis (HLH), a hyperinflammatory syndrome leading to organ damage and death, may arise as a complication of lymphomas (L-HLH). L-HLH diagnosis is challenging and optimal treatment strategies, influenced by factors such as timing of onset, lymphoma subtype and disease severity, remain ill-defined. This narrative review summarises recent evidence to support clinicians in navigating the competing priorities posed by L-HLH, including the urgent need to control inflammation, establish a diagnosis and initiate lymphoma-directed therapy, while minimising toxicity and avoiding unnecessary immunosuppression.Recent findings: While HLH-94 and H-score diagnostic criteria were not specifically designed for L-HLH, the optimised HLH inflammatory index (OHI) was developed in L-HLH patients and predicts the risk of multiorgan failure (MOF) but also benefit from etoposide. Recent evidence also highlights improved survival with early administration of lymphoma targeting drugs while, in critically unwell patients, non-myelosuppressive treatment with anakinra, ruxolitinib and intravenous immunoglobulins (IVIg) might offer a survival advantage. Finally, novel markers such as C-X-C motif chemokine ligand 9 (CXCL-9), recently shown to identify patients responding to interferon γ blockade, might become more widely available in the future.Summary: L-HLH encompasses a wide range of clinical presentations that force clinicians to balance competing priorities. Recent evidence improves patients stratification and supports early administration of lymphoma targeting drugs when feasible, etoposide in high risk patients and non-myelosuppressive regimens in critically unwell patients.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"382-390"},"PeriodicalIF":2.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence in gynecologic oncology: bridging the gap between digital innovation and clinical utility. 妇科肿瘤学中的人工智能：弥合数字创新与临床应用之间的差距。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-09-01 Epub Date: 2026-08-06 DOI: 10.1097/CCO.0000000000001264

Ignacio Zapardiel

引用次数: 0

Lifestyle medicine for cancer survivorship. 癌症幸存者的生活方式药物。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-06-04 DOI: 10.1097/CCO.0000000000001243

Hundal Jasmin, Peshin Supriya

{"title":"Lifestyle medicine for cancer survivorship.","authors":"Hundal Jasmin, Peshin Supriya","doi":"10.1097/CCO.0000000000001243","DOIUrl":"10.1097/CCO.0000000000001243","url":null,"abstract":"Purpose of review: Cancer survivorship is increasingly characterized by long-term treatment sequelae, including cardiometabolic disease, fatigue, sleep disturbance, psychological distress, and risk of second malignancies. As survivorship populations expand, there is growing recognition that traditional symptom-focused follow-up does not adequately address modifiable drivers of long-term morbidity. This review evaluates lifestyle medicine as a structured framework integrating physical activity, nutrition, sleep health, psychological well being, and substance cessation to improve survivorship outcomes across solid tumors and hematologic malignancies.Recent findings: Evidence from randomized trials, cohort studies, and consensus guidelines demonstrates that lifestyle interventions influence systemic inflammation, immune function, metabolic regulation, and functional capacity. Physical activity improves fatigue, cardiorespiratory fitness, and quality of life, while plant-forward dietary patterns are associated with improved survival outcomes. Sleep optimization and stress reduction interventions improve inflammatory signaling and psychological outcomes. Tobacco cessation and alcohol reduction reduce recurrence risk and mortality. Emerging literature highlights the relevance of cardiometabolic pathways and behavioral interventions as modifiable determinants of survivorship trajectories.Summary: Lifestyle medicine provides a biologically plausible and clinically actionable framework to address shared mechanisms underlying cancer recurrence, treatment toxicity, and chronic disease risk. Integration of multidisciplinary interventions and digital health tools may enable scalable survivorship models focused on prevention, functional recovery, and long-term health optimization. Future research should prioritize mechanistic studies and pragmatic trials evaluating multimodal interventions across diverse cancer populations.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"38 4","pages":"275-281"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-05-14 DOI: 10.1097/CCO.0000000000001245

Zoé Servais, Yves Libert, Magali Lahaye, Charlotte Grégoire, Isabelle Merckaert

{"title":"Cancer-related cognitive impairment in adolescents and young adults with cancer: a scoping review.","authors":"Zoé Servais, Yves Libert, Magali Lahaye, Charlotte Grégoire, Isabelle Merckaert","doi":"10.1097/CCO.0000000000001245","DOIUrl":"10.1097/CCO.0000000000001245","url":null,"abstract":"Purpose of review: Cancer-related cognitive impairment (CRCI) is a frequent and clinically meaningful consequence of cancer, yet current evidence is largely derived from older adult populations. Adolescents and young adults (AYAs) may be particularly vulnerable due to ongoing neurodevelopment, high cognitive demands, and cancer-related biological and psychosocial stressors. This review is timely given the growing interest in biological mechanisms and preventive models of CRCI, alongside the persistent lack of AYA-specific syntheses addressing cognitive trajectories, mechanisms, and optimal intervention timing.Recent findings: Approximately 25-30% of AYAs experience CRCI, most commonly affecting attention, processing speed, executive functioning, and working memory. Cognitive alterations may be detectable prior to treatment initiation and can persist across the cancer trajectory. Emerging AYA-specific evidence implicates biological mechanisms such as systemic inflammation and altered neuroplasticity, including changes in brain-derived neurotrophic factor (BDNF). A consistent dissociation between subjective cognitive complaints and objective performance is observed, underscoring the functional impact of subtle inefficiencies in academic and early professional contexts. While non-pharmacological interventions show promise in the general CRCI literature, early and AYA-specific preventive interventions remain scarce.Summary: CRCI in AYAs should be conceptualized as a dynamic, biologically grounded process embedded within ongoing neurodevelopment. Early, developmentally sensitive, and multimodal interventions may represent a key opportunity to preserve long-term cognitive, functional, and psychosocial outcomes in this vulnerable population.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"283-296"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148148942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reframing distress in oncology: the potential of psychedelic-assisted therapy. 重新定义肿瘤中的痛苦：致幻剂辅助治疗的潜力。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-05-14 DOI: 10.1097/CCO.0000000000001242

Fatima Zohra Moujahid, Olivier Taymans

{"title":"Reframing distress in oncology: the potential of psychedelic-assisted therapy.","authors":"Fatima Zohra Moujahid, Olivier Taymans","doi":"10.1097/CCO.0000000000001242","DOIUrl":"10.1097/CCO.0000000000001242","url":null,"abstract":"Purpose of review: Psychological and existential distress are common across the cancer trajectory and can impair quality of life, treatment adherence, and family functioning. Although psychosocial and pharmacological interventions provide meaningful support, their overall effects are often modest. This review examines the emerging role of psychedelic-assisted therapy (PAT) as a potential approach to better address the multidimensional nature of cancer-related distress.Recent findings: PAT combines psychedelic compounds with structured psychotherapeutic support and typically includes preparatory sessions, a supervised dosing experience, and post-session integration. Psychedelics are thought to enhance neuroplasticity and emotional flexibility, creating conditions that may support sustained psychological change. Recent trials in advanced cancer populations report improvements in anxiety, depression, pain-related distress, and quality of life following one or two dosing sessions.Summary: Current evidence remains limited by small and demographically narrow samples, variable treatment protocols, and potential expectancy effects. Implementation also presents practical challenges, including training requirements, time demands, and resource intensity. Despite these limitations, growing international interest may facilitate further development, supporting the need for careful and rigorous evaluation of PAT as a novel intervention for cancer-related distress.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"297-301"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148027976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours. 全身放射性核素治疗胃、肠、胰神经内分泌肿瘤。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-06-04 DOI: 10.1097/CCO.0000000000001252

Zahra Noordally, Magdalena Mileva, Alain Hendlisz, Ioannis Karfis

{"title":"Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.","authors":"Zahra Noordally, Magdalena Mileva, Alain Hendlisz, Ioannis Karfis","doi":"10.1097/CCO.0000000000001252","DOIUrl":"10.1097/CCO.0000000000001252","url":null,"abstract":"Purpose of review: Systemic radionuclide therapy has become a cornerstone in the management of advanced gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs). Following the establishment of β-emitting peptide receptor radionuclide therapy (PRRT) as an effective treatment for somatostatin receptor positive NETs, recent clinical and translational advances have substantially expanded its therapeutic scope. Several pivotal randomised trials published within the past 18 months justify a reassessment of radionuclide treatment strategies in GEP-NETs.Recent findings: Recently published results of randomised phase III trials support a broader and more strategic use of PRRT, such as in selected high-grade well differentiated NETs. Direct comparisons of PRRT and targeted therapies redefine therapeutic sequencing. Radiosensitising combinations and next-generation theranostic platforms, including alpha-emitting radionuclides, are entering late-phase development.Summary: Radionuclide therapy in GEP-NETs is transitioning from a late-line option toward a flexible, biology-driven treatment strategy with important implications for clinical practice.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"38 4","pages":"351-358"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From dose to exposure? rethinking fluoropyrimidines as immune checkpoint partners in gastrointestinal cancers. 从剂量到暴露？重新思考氟嘧啶作为胃肠道癌症免疫检查点伙伴。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-06-04 DOI: 10.1097/CCO.0000000000001248

Alain Hendlisz, Leila Shaza, Thierry De Grez, Ahmad Awada

{"title":"From dose to exposure? rethinking fluoropyrimidines as immune checkpoint partners in gastrointestinal cancers.","authors":"Alain Hendlisz, Leila Shaza, Thierry De Grez, Ahmad Awada","doi":"10.1097/CCO.0000000000001248","DOIUrl":"10.1097/CCO.0000000000001248","url":null,"abstract":"Purpose of review: Fluoropyrimidine regimens in gastrointestinal oncology have evolved empirically. Bolus 5-fluorouracil (5-FU)-containing combinations now coexist with continuous metronomic schedules and oral prodrugs, while immune checkpoint inhibitors (ICIs) seek chemotherapy partners for microsatellite-stable (MSS) gastrointestinal cancers. This review examines the intersection of bolus omission, metronomic scheduling, and biomarker-selected immunochemotherapy and proposes a shift from dose-based to exposure-based paradigms.Recent findings: A real-world cohort of 11 765 patients showed that bolus omission from FOLFOX, FOLFIRI and FOLFIRINOX preserved survival and approximately halved grade 3-4 haematological toxicity. CAIRO3 validated low-dose continuous capecitabine maintenance, pharmacologically consistent with metronomic dosing. Preclinical murine studies suggest that fluoropyrimidine immune effects are dose-, schedule- and partner-dependent, with peak exposure activating NLRP3-driven pro-tumour pathways; relevance to human disease remains hypothetical. Two recent signals (POCHI and MEDITREME) share early-line treatment, immune or molecular enrichment, and an oxaliplatin-driven immunogenic cell death inducer; POCHI also avoids intravenous 5-FU bolus through its CAPOX backbone.Summary: Recent failures of chemo-immunotherapy in MSS gastrointestinal cancers may partly reflect immunologically suboptimal chemotherapy backbones. Optimal outcomes likely require joint consideration of schedule, biomarker selection, and immunogenic partner. Prospective trials testing chemotherapy schedules are warranted.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"338-350"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148148963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer-related fatigue in adolescents and young adults. 青少年和年轻人的癌症相关疲劳。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-05-14 DOI: 10.1097/CCO.0000000000001241

Farnaz Moghaddamfar, Magali Lahaye, Yves Libert, Isabelle Merckaert, Charlotte Grégoire

{"title":"Cancer-related fatigue in adolescents and young adults.","authors":"Farnaz Moghaddamfar, Magali Lahaye, Yves Libert, Isabelle Merckaert, Charlotte Grégoire","doi":"10.1097/CCO.0000000000001241","DOIUrl":"10.1097/CCO.0000000000001241","url":null,"abstract":"Purpose of review: This review aims to provide a comprehensive overview of the prevalence, associated factors, and consequences of cancer-related fatigue (CRF) in adolescents and young adults (AYAs) with cancer, and to examine interventions designed to manage CRF.Recent findings: This review included 20 articles, providing an overview of CRF in AYAs. Several studies reported a high prevalence of CRF in AYAs with cancer, both during treatment and in survivorship, associated with reduced quality of life and well-being. Most tested interventions targeted physical activity, including supervised and unsupervised programs, while others focused on self-management in survivorship or involved live music.Summary: This review underscored that CRF is prevalent among AYAs with cancer, during treatment and throughout survivorship, with substantial repercussions for overall quality of life. These findings highlight the importance of assessing CRF and implementing supportive interventions to reduce its burden. Future research should advance the development of tailored, developmentally appropriate, and engaging strategies to effectively address CRF in this population.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"302-309"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148027957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epithelioid sarcoma: from SMARCB1 loss to therapeutic vulnerabilities. 上皮样肉瘤：从SMARCB1缺失到治疗脆弱性。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-03-24 DOI: 10.1097/CCO.0000000000001236

Pawel Sobczuk, Cristina Gómez-Palmero, César Serrano

{"title":"Epithelioid sarcoma: from SMARCB1 loss to therapeutic vulnerabilities.","authors":"Pawel Sobczuk, Cristina Gómez-Palmero, César Serrano","doi":"10.1097/CCO.0000000000001236","DOIUrl":"10.1097/CCO.0000000000001236","url":null,"abstract":"Purpose of review: Epithelioid sarcoma (ES) is one of the ultra-rare subtypes of soft tissue sarcomas, with an incidence <0.5 new cases/million/year. It is characterized by loss of SMARCB1 expression, a member of chromatin remodelling complexes, leading to transcriptional dysregulation and dependence on the PRC2 complex, with its histone methyltransferase EZH2. This review summarizes the current therapeutic landscape of ES and explores advances in its molecular characterization as well as potential new treatment options.Recent findings: Loss of SMARCB1 in ES is mostly related to homozygous deletion of its locus in chromosome 22. Lack of SMARCB1 leads to global transcriptional changes and the identification of two distinct molecular subtypes that closely resemble the classical and proximal histological subtypes of ES. Transcriptional analyses revealed new potential therapeutic targets, including MYC, mTOR, and TEK. Dependence on EZH2 led to the approval of the EZH2 inhibitor tazemetostat for the treatment of advanced ES; however, multiple resistance mechanisms that decreased its activity have been characterized, and its use recently discontinued due to unexpected secondary hematological malignancies.Summary: Despite progress in understanding ES biology, treatment options are limited, and prognosis remains poor. Further studies are needed, but the rarity of the disease limits opportunities for conducting dedicated clinical trials or broader molecular characterization.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"319-326"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pain management in pancreatic cancer: time to change our strategy! 胰腺癌疼痛管理：是时候改变我们的策略了！

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-06-04 DOI: 10.1097/CCO.0000000000001251

Daniel Blero, Alain Hendlisz

{"title":"Pain management in pancreatic cancer: time to change our strategy!","authors":"Daniel Blero, Alain Hendlisz","doi":"10.1097/CCO.0000000000001251","DOIUrl":"10.1097/CCO.0000000000001251","url":null,"abstract":"Pain affects 70-80% of patients with pancreatic adenocarcinoma and remains inadequately controlled in more than half of cases. Beyond its impact on quality of life, pain is now recognized as an independent prognostic factor, reflecting the unique neurobiological features of this malignancy. Perineural invasion drives a bidirectional dialogue between cancer cells and the peripheral nervous system, in which neurotrophic factors, neuropeptides, and immune mediators fuel both nociception and tumour progression. Current pain management relies on the WHO analgesic ladder supplemented by adjuvant agents (gabapentinoids, duloxetine, corticosteroids) and interventional procedures including celiac plexus neurolysis, intrathecal opioid delivery, and palliative radiotherapy. Recent advances, notably celiac plexus radiosurgery and evidence favouring early neurolysis, challenge the prevailing reactive approach. This review examines the pathophysiology of pancreatic cancer pain, critically appraises available treatments, identifies gaps in current evidence, and argues for a proactive, multimodal strategy initiated at diagnosis rather than reserved for refractory disease.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"38 4","pages":"359-363"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0